Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Forteo launch

Executive Summary

Lilly expects to launch the osteoporosis drug Forteo "at the end of this year or early next year, depending on the timing of...approval in the fourth quarter," Exec VP August Watanabe tells analysts at Banc of America Securities Conference Sept. 10. In July, FDA's Endocrinologic & Metabolic Drugs Advisory Committee recommended the drug for the treatment of osteoporosis in postmenopausal women but said the indication should be restricted to high-risk patients and second-line use (1"The Pink Sheet" July 30, p. 3)

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts